KALV

KalVista Pharmaceuticals, Inc.

12.33 USD
-0.25 (-1.99%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

KalVista Pharmaceuticals, Inc. stock is down -7.78% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
05 Feb 20:55 15 Mar, 2024 12.50 CALL 62 2184
05 Feb 20:55 15 Mar, 2024 12.50 CALL 77 2184
05 Feb 20:57 15 Mar, 2024 12.50 CALL 84 2184
05 Feb 20:57 15 Mar, 2024 12.50 CALL 43 2184
05 Feb 20:57 15 Mar, 2024 12.50 CALL 75 2184
05 Feb 20:57 15 Mar, 2024 12.50 CALL 81 2184
05 Feb 20:57 15 Mar, 2024 12.50 CALL 258 2184
12 Feb 16:03 16 Feb, 2024 17.50 CALL 520 2605
21 Feb 14:42 21 Jun, 2024 12.50 CALL 100 4
22 Feb 15:18 19 Apr, 2024 12.50 PUT 4986 10

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME) products.

  • HC Wainwright & Co.
    Wed Feb 14, 06:33
    buy
    confirm
  • Needham
    Tue Feb 13, 14:16
    buy
    confirm